Related Experiment Videos
Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and
Summary
The OPEC chemotherapy regimen, including vincristine, cyclophosphamide, cisplatin, and VM-26, shows promising response rates for advanced neuroblastoma in children. This less toxic regimen achieved similar tumor response to OPEC-D with manageable side effects.
Area of Science:
- Pediatric Oncology
- Medical Chemotherapy
- Neuroblastoma Research
Background:
- Neuroblastoma is a common pediatric cancer.
- Advanced stages (III-IV) require effective initial treatment.
- Previous regimens showed moderate response rates.
Purpose of the Study:
- To evaluate the efficacy of two chemotherapy regimens for newly diagnosed stage III or IV neuroblastoma.
- To compare the response rates and toxicity of OPEC versus OPEC-D regimens.
- To assess the effectiveness of OPEC as a less toxic alternative.
Main Methods:
- Forty-two children over one year old with newly diagnosed stage III or IV neuroblastoma were treated.
- Regimens included vincristine, cyclophosphamide, cisplatin, and VM-26 (OPEC) or OPEC plus doxorubicin (OPEC-D).
- Treatment adherence and patient response were monitored, along with toxicity, including cisplatin-induced morbidity.
Main Results:
- Overall good partial response was achieved in 74% of patients (31/42).
- Adherence to protocol yielded a 78% response rate (28/36).
- The OPEC regimen demonstrated comparable tumor response to the less toxic OPEC-D regimen, with manageable cisplatin-related side effects.
Conclusions:
- The OPEC regimen is an effective and less toxic treatment option for advanced neuroblastoma.
- Careful monitoring can mitigate cisplatin-induced toxicity.
- Further testing of OPEC or equivalent regimens in other centers is recommended for advanced neuroblastoma treatment.